Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcripts
Agios Pharmaceuticals, Inc.'s Latest Earnings Call - June 13, 2026
In Q2 2026, Agios Pharmaceuticals reported significant progress in its rare disease portfolio, particularly with mitapivat in thalassemia and sickle cell disease. Revenue and earnings specifics were not provided, but the focus was on clinical data and pipeline advancements. The company highlighted the transition from a single-asset to a multi-asset platform, emphasizing the potential of mitapivat and other assets like AG-236 in polycythemia vera. Management maintained guidance and expressed confidence in upcoming catalysts, including the U.S. commercial launch of AQVESME and the sNDA for mitapivat in sickle cell disease.
Reported metrics
| Metric | Value |
|---|---|
| Hemoglobin Response in Sickle Cell Disease | 40.6% (beat) |
| Reduction in Transfusion Requirements | 41% reduction (positive) |
| Thalassemia Hemoglobin Response | 60% response rate (positive) |
| AG-236 Development | Late-stage development (positive) |
Guidance from management
Management maintained guidance, emphasizing upcoming catalysts such as the U.S. launch of AQVESME and the sNDA for mitapivat in sickle cell disease. They highlighted multiple near and midterm catalysts over the next 12 to 24 months.
What management said
I want to dive right in and talk a little bit about the state of sickle cell disease as it exists today. you both collectively spent decades caring for patients with this illness. How would you characterize the burden of this particular disease in patients today?
That's really important clinical framing. Thank you for those perspectives. I'd like to dive a little bit into the pathophysiology around the disease and kind of get a sense from the both of you around the importance of addressing chronic anemia and hemolysis in the overall management of sickle cell disease as you think about patients holistically. Let's go ahead and start with you, Dr. Anderson.
What analysts pressed on
Analysts questioned the potential label for mitapivat's accelerated approval and its competitive positioning against other therapies. Concerns were also raised about the correlation between transfusion burden reduction and other clinical benefits.
Main topics on the call
- Mitapivat in Sickle Cell Disease — Mitapivat demonstrated a 40.6% hemoglobin response in sickle cell disease patients, with significant reductions in transfusion requirements and improvements in fatigue. Management noted, 'Mitapivat represents a different...
- Thalassemia Data — Long-term data from the ENERGIZE Phase III trial showed sustained hemoglobin improvements in thalassemia patients. 'The mean duration of hemoglobin response more than doubled,' stated management.
- Pipeline Expansion — Agios announced the progression of AG-236 into late-stage development for polycythemia vera, highlighting a 'clear dose-dependent hepcidin induction.'
- Commercial Strategy — The company is focused on scaling the U.S. launch of AQVESME in thalassemia and preparing for mitapivat's potential launch in sickle cell disease. 'Our commercial organization is focused on... scaling the U.S. commercial...
Read the full Agios Pharmaceuticals, Inc. transcript (June 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (AGIO) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 75 calls on record spanning January 13, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 75 Agios Pharmaceuticals, Inc. earnings call transcripts on record, spanning January 13, 2020 to July 30, 2026. Based on this history, Agios Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- AGIO
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 75
- First call
- January 13, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly